Parabilis Medicines, previously known as FogPharma, is a biotech company that has changed its name to better reflect its mission. The new name highlights their aim to push the boundaries of treating serious diseases and make their medicines accessible worldwide.
Unlike many companies that rebrand to move away from a negative image, FogPharma chose to rebrand during a successful period. Founded by Greg Verdine in 2015, the company gained recognition in 2023 and secured significant funding in 2024.
The new name, Parabilis, signifies going beyond the possible and achieving goals, representing the company’s commitment to innovation and accessibility. CEO Mathai Mammen emphasizes that the name reflects the team’s ambitious yet practical approach to developing medicines for unmet needs.
The company remains focused on advancing its main drug candidate, FOG-001, which targets specific interactions in the body that could be effective against multiple mutations. This drug was developed using Parabilis’ Helicon platform, which now incorporates AI and new technologies to create and improve peptide-based treatments for challenging targets.